Acorda Therapeutics

Acorda Therapeutics, Inc.
Company type	Public
Industry	Health care; Biotechnology;
Founded	1995; 29 years ago
Founder	Ron Cohen
Headquarters	420 Saw Mill River Road, Ardsley, New York, United States
Key people	Ron Cohen (CEO)
Products	Ampyra; Inbrija;
Revenue	US$192.408 million (2019)
Operating income	US$−311.632 million (2019)
Net income	US$−272.966 million (2019)
Total assets	US$799.718 million (2019)
Total equity	US$310.820 million (2019)
Number of employees	344 (2020)
Website	acorda.com

Acorda Therapeutics, Inc. is an American biotechnology company based in Pearl River, New York. The company develops therapies that improve neurological function in people with Parkinson's disease, multiple sclerosis and other neurological disorders. Acorda Therapeutics manufactures and markets the drugs Inbrija (levodopa inhalation powder) and Ampyra (dalfampridine) in the United States.

^ ^a ^b "FAQs". Investor Resources. Acorda. Retrieved 2019-09-24.^{[self-published source]}
^ Alterio, Julie Moran (June 4, 2007). "In pursuit of MS drug". The Journal News. Vol. 119, no. 30. White Plains, New York: Gannett. pp. 1C, 10C – via Newspapers.com. Second page of article.
^ ^a ^b ^c ^d ^e ^f "Acorda Therapeutics 2020 Annual Report (Form 10-K)" (PDF). www.ir.acorda.com. U.S. Securities and Exchange Commission. February 20, 2020.

[InvestorFAQ-1] "FAQs". Investor Resources. Acorda. Retrieved 2019-09-24.^{[self-published source]}

[alterio2007-2] Alterio, Julie Moran (June 4, 2007). "In pursuit of MS drug". The Journal News. Vol. 119, no. 30. White Plains, New York: Gannett. pp. 1C, 10C – via Newspapers.com. Second page of article.

[aco-3] ^ ^a ^b ^c ^d ^e ^f "Acorda Therapeutics 2020 Annual Report (Form 10-K)" (PDF). www.ir.acorda.com. U.S. Securities and Exchange Commission. February 20, 2020.

[1]

[2]

[3]